1 – 10 of 37
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Quality of life in a large multinational haemophilia B cohort (The B-Natural study) – Unmet needs remain
(
- Contribution to journal › Article
- 2021
-
Mark
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)
(
- Contribution to journal › Article
-
Mark
The B-Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B
(
- Contribution to journal › Article
- 2017
-
Mark
European retrospective study of real-life haemophilia treatment
(
- Contribution to journal › Article
- 2011
-
Mark
Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).
(
- Contribution to journal › Article
- 2008
-
Mark
Patients' and their family members' understanding of the genetics of type 1 von Willebrand disease.
(
- Contribution to journal › Letter
-
Mark
Asn1421Lys mutation in the glycoprotein Ib binding domain impairs - ristocetin and botrocetin - mediated binding of von Willebrand factor to platelets
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.116-116(
- Contribution to journal › Published meeting abstract
-
Mark
A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
(
- Contribution to journal › Scientific review
-
Mark
N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
(
- Contribution to journal › Article
-
Mark
Characterization of a novel mutation in the von Willebrand factor propeptide in a distinct subtype of recessive von Willebrand disease.
(
- Contribution to journal › Article